**Subject: Risk Assessment for New Clinical Trial**

---

**From:** Brendan Gordon <brenthorne@example.org>  
**To:** Connie Weiss <qgomez@example.org>  
**Date:** October 12, 2023, 09:13 AM  

Hi Connie,

I hope this message finds you well. I’m reaching out to discuss the risk assessment for the upcoming clinical trial involving the new oncology drug, currently code-named “Project Solstice.” 

Given your expertise in dramatherapy, your insights into patient interactions could be invaluable in identifying potential psychosocial risks that might arise during the study. We're particularly interested in how we can mitigate risks related to patient engagement and compliance, as these are critical factors for the trial's success.

Could we schedule a meeting this week to go over the preliminary risk matrix and your initial thoughts? I’m available Thursday or Friday afternoon. Please let me know what works best for you.

Thanks in advance for your input.

Best,  
Brendan Gordon  
Risk Analyst  
Merck  
brenthorne@example.org  
(555) 018-2345  

---

**From:** Connie Weiss <qgomez@example.org>  
**To:** Brendan Gordon <brenthorne@example.org>  
**Date:** October 12, 2023, 11:47 AM  

Hi Brendan,

Thanks for reaching out. I'm keen to contribute to the risk assessment for Project Solstice, as patient interaction is indeed a crucial element. Understanding how patients emotionally engage with the trial process can significantly impact their adherence and overall experience.

I’m available this Friday at 2 PM, which should give us enough time to delve into the details. I'll bring some case studies from previous trials that highlight effective strategies for managing psychosocial risks. We can meet in my office at the Downtown HQ, Room 5B. Let me know if that works for you.

Looking forward to our discussion.

Best regards,  
Connie Weiss  
Dramatherapist  
Merck  
qgomez@example.org  
(555) 019-8765  

P.S. Just a heads-up, I’ll be on leave from October 20-27, so if any follow-ups are needed, we might want to schedule them before then.